Alkeon Capital Management
XLRN

Alkeon Capital Management’s Acceleron Pharma XLRN Stock Holding History

Alkeon Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,245,412
Closed -$214M – 185
2021
Q3 		$214M Sell
1,245,412
-2,719
-0.2% -$356K 0.36% 67
2021
Q2 		$157M Sell
1,248,131
-473,600
-28% -$59.7M 0.23% 81
2021
Q1 		$233M Buy
1,721,731
+3,310
+0.2% +$428K 0.35% 61
2020
Q4 		$220M Buy
1,718,421
+92,815
+6% +$10.9M 0.36% 56
2020
Q3 		$183M Buy
1,625,606
+125,000
+8% +$12.4M 0.34% 54
2020
Q2 		$143M Buy
1,500,606
+122,656
+9% +$11.8M 0.36% 55
2020
Q1 		$124M Buy
1,377,950
+800,000
+138% +$62.2M 0.53% 50
2019
Q4 		$30.6M Sell
577,950
-366,000
-39% -$16.7M 0.11% 96
2019
Q3 		$37.3M Hold
943,950
– – 0.13% 93
2019
Q2 		$38.8M Buy
943,950
+100,000
+12% +$4.14M 0.15% 94
2019
Q1 		$39.3M Buy
843,950
+470,000
+126% +$20.6M 0.2% 93
2018
Q4 		$16.3M Buy
373,950
+101,621
+37% +$5.08M 0.11% 104
2018
Q3 		$15.6M Buy
+272,329
New +$13.4M 0.07% 101

Alkeon Capital Management's XLRN Position: Q4 2021 in Review

Alkeon Capital Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 1,245,412 shares — an estimated $214M sold.

Alkeon Capital Management first reported a position in XLRN in Q3 2018 and held it in 13 quarters. The position peaked at $233M in Q1 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Alkeon Capital Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Alkeon Capital Management sold 1,245,412 Acceleron Pharma shares in Q4 2021, an estimated $214M.
  • Alkeon Capital Management first reported a position in Acceleron Pharma in Q3 2018 and held it in 13 quarters.
  • Alkeon Capital Management's Acceleron Pharma position peaked at $233M in Q1 2021.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Alkeon Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.